{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:02:10Z","timestamp":1771977730894,"version":"3.50.1"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Venous thromboembolism (VTE) is a common complication among hospitalized patients. Low-molecular-weight heparin (LMWH) is recommended for thromboprophylaxis, but its benefits in non-surgical patients, particularly those receiving dual antiplatelet therapy (DAPT), remain unclear. Currently, evidence on the risks and benefits of LMWH thromboprophylaxis in patients on DAPT is lacking.<\/jats:p>\n                  <jats:p>This retrospective cohort study included patients hospitalized in the cardiology departments of two hospitals of LMU University Munich between May 2015 and April 2025. Patients receiving DAPT, defined as treatment with aspirin and a P2Y12 inhibitor, were analyzed. The study population was divided into two groups: those who received LMWH prophylaxis and those who did not. The primary endpoint was the incidence of VTE during hospitalization, confirmed through imaging techniques. Secondary endpoints included the need for erythrocyte transfusion.<\/jats:p>\n                  <jats:p>A total of 8,619 patients receiving DAPT were included, of which 2,378 were receiving LMWH prophylaxis. The incidence of VTE was very low and did not differ between the LMWH and non-LMWH groups (0.04% versus 0%, p\u2009=\u20090.28). Subgroup analysis revealed higher bleeding rates as mirrored by more erythrocyte transfusions in the LMWH group (9.4 versus 5.1%, p\u2009=\u20090.004).<\/jats:p>\n                  <jats:p>In patients receiving DAPT, LMWH thromboprophylaxis was associated with a comparably low incidence of VTE but a higher rate of erythrocyte transfusions in subgroup analysis.<\/jats:p>","DOI":"10.1055\/a-2615-4785","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:01:01Z","timestamp":1747684861000},"page":"310-318","source":"Crossref","is-referenced-by-count":0,"title":["Thromboembolic Risk among Patients on Dual Antiplatelet Therapy with or without Heparin Thromboprophylaxis"],"prefix":"10.1055","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-6449","authenticated-orcid":false,"given":"Jonas","family":"Gmeiner","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"},{"name":"Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Kr\u00e4chan","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Wasner","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Marchant Seiter","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Weckbach","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Stark","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"},{"name":"Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Hausleiter","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"},{"name":"Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"},{"name":"Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Scherer","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital, LMU Munich, Munich, Germany"},{"name":"Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"P L Lutsey","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"07","key":"ref2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000138928.83266.24","article-title":"Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients","volume":"110","author":"A Leizorovicz","year":"2004","journal-title":"Circulation"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199909093411103","article-title":"A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients","volume":"341","author":"M M Samama","year":"1999","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"S R Kahn","year":"2012","journal-title":"Chest"},{"issue":"08","key":"ref5","doi-asserted-by":"crossref","first-page":"EVIDoa2200332","DOI":"10.1056\/EVIDoa2200332","article-title":"Enoxaparin versus placebo to prevent symptomatic venous thromboembolism in hospitalized older adult medical patients","volume":"2","author":"D Mottier","year":"2023","journal-title":"NEJM Evid"},{"issue":"26","key":"ref6","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1056\/NEJMoa1111288","article-title":"Low-molecular-weight heparin and mortality in acutely ill medical patients","volume":"365","author":"A K Kakkar","year":"2011","journal-title":"N Engl J Med"},{"issue":"9212","key":"ref7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial","volume":"355","author":"P EPPTC Group","year":"2000","journal-title":"Lancet"},{"issue":"6923","key":"ref8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.308.6923.235","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2013III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration","volume":"308","year":"1994","journal-title":"BMJ"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2205973","article-title":"Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture","volume":"388","author":"R V O'Toole","year":"2023","journal-title":"N Engl J Med"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1378\/chest.10-1944","article-title":"Predictive and associative models to identify hospitalized medical patients at risk for VTE","volume":"140","author":"A C Spyropoulos","year":"2011","journal-title":"Chest"},{"issue":"08","key":"ref11","first-page":"1","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"D E Ho","year":"2011","journal-title":"J Stat Softw"},{"issue":"05","key":"ref12","first-page":"CD003747","article-title":"Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)","volume":"2014","author":"R Alikhan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1538-7836.2007.02847.x","article-title":"Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis","volume":"6","author":"N S Lloyd","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"14","key":"ref14","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archinte.167.14.1476","article-title":"Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials","volume":"167","author":"L Wein","year":"2007","journal-title":"Arch Intern Med"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.thromres.2011.12.005","article-title":"Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty","volume":"130","author":"B I Eriksson","year":"2012","journal-title":"Thromb Res"},{"issue":"01","key":"ref16","first-page":"183","article-title":"Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding","volume":"108","author":"R J Friedman","year":"2012","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/jth.14807","article-title":"Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: systematic review and meta-analysis","volume":"18","author":"E Valeriani","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"15","key":"ref18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"M Lamberts","year":"2014","journal-title":"Circulation"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"e200107","DOI":"10.1001\/jamanetworkopen.2020.0107","article-title":"Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation","volume":"3","author":"K AA Fox","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"22","key":"ref21","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"M S Cho","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2615-4785.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:32:03Z","timestamp":1771975923000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2615-4785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":21,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,2,24]]},"published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2615-4785","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,19]]},"published":{"date-parts":[[2025,5,19]]}}}